Literature DB >> 19301031

Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies.

Sven Gunia1, Stefan Koch, Matthias May, Manfred Dietel, Andreas Erbersdobler.   

Abstract

Clinical management of incidental prostate cancer (IPC) remains challenging since its clinical course cannot be predicted by conventional histopathology. Aiming to define predictive factors in IPC, we correlated the immunohistochemically detected expression of prostate-specific antigen (PSA), prostatic acid phosphatase (PSAP), alpha-methylacyl-CoA racemase (AMACR, p504s), and androgen receptor in transurethral resection specimens with Gleason scores and histologic staging on the corresponding radicals in a cohort of 54 patients (mean age, 65.9 years; range, 49-80 years). PSAP expression showed a significant correlation with tumor staging (rho = -0.37; p = 0.02) but not with Gleason scores (rho = -0.06; p = 0.69). K-statistics revealed a highly significant moderate interobserver agreement concerning the evaluation of PSAP staining (K = 0.47; p < 0.001). In contrast, the other markers assessed failed to correlate with conventional histopathology. Therefore, PSAP might be predictive of tumor stage in IPC and represent a valuable adjunct for clinical decisions in terms of individual therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301031     DOI: 10.1007/s00428-009-0759-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

1.  Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.

Authors:  Shan Zha; Sacha Ferdinandusse; Jessica L Hicks; Simone Denis; Thomas A Dunn; Ronald J Wanders; Jun Luo; Angelo M De Marzo; William B Isaacs
Journal:  Prostate       Date:  2005-06-01       Impact factor: 4.104

2.  Early carcinoma of the prostate: comparison of stages A and B.

Authors:  R Barnes; A Hirst; R Rosenquist
Journal:  J Urol       Date:  1976-04       Impact factor: 7.450

Review 3.  Incidental prostatic cancer: repeat TURP or biopsy?

Authors:  Pasquale Martino; Silvano Palazzo; Michele Battaglia; Giuseppe Lucarelli; Francesco Paolo Selvaggi
Journal:  Urol Int       Date:  2004       Impact factor: 2.089

4.  The present status of radical prostatectomy for stages A and B prostatic cancer.

Authors:  H J Jewett
Journal:  Urol Clin North Am       Date:  1975-02       Impact factor: 2.241

5.  Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?

Authors:  Roberta Mazzucchelli; Francesca Barbisan; Marina Scarpelli; Antonio Lopez-Beltran; Theodorus H van der Kwast; Liang Cheng; Rodolfo Montironi
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

Review 6.  A retrospective and prospective overview of prostate-specific antigen.

Authors:  R J Ablin
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

7.  Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification.

Authors:  C A Sheldon; R D Williams; E E Fraley
Journal:  J Urol       Date:  1980-11       Impact factor: 7.450

8.  The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer.

Authors:  D R Greene; S Egawa; G Neerhut; W Flanagan; T M Wheeler; P T Scardino
Journal:  J Urol       Date:  1991-02       Impact factor: 7.450

Review 9.  Immunohistochemistry in diagnostic surgical pathology of the prostate.

Authors:  Omar Hameed; Peter A Humphrey
Journal:  Semin Diagn Pathol       Date:  2005-02       Impact factor: 3.464

Review 10.  Incidental carcinoma of the prostate.

Authors:  G van Andel; R Vleeming; K Kurth; T M de Reijke
Journal:  Semin Surg Oncol       Date:  1995 Jan-Feb
View more
  14 in total

1.  Impact of semen-derived amyloid (SEVI) on sperm viability and motility: its implication in male reproductive fitness.

Authors:  Vijay Kumar; Pradeep G Kumar; Jay Kant Yadav
Journal:  Eur Biophys J       Date:  2019-08-07       Impact factor: 1.733

2.  Screening and characterization of a novel RNA aptamer that specifically binds to human prostatic acid phosphatase and human prostate cancer cells.

Authors:  Hoon Young Kong; Jonghoe Byun
Journal:  Mol Cells       Date:  2015-01-15       Impact factor: 5.034

3.  MUC1 expression in incidental prostate cancer predicts staging and grading on the subsequent radical prostatectomy.

Authors:  Sven Gunia; Matthias May; Stefan Koch; Manfred Dietel; Andreas Erbersdobler
Journal:  Pathol Oncol Res       Date:  2009-11-27       Impact factor: 3.201

4.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

5.  Development of multigene expression signature maps at the protein level from digitized immunohistochemistry slides.

Authors:  Gregory J Metzger; Stephen C Dankbar; Jonathan Henriksen; Anthony E Rizzardi; Nikolaus K Rosener; Stephen C Schmechel
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

Review 6.  Emerging roles of human prostatic Acid phosphatase.

Authors:  Hoon Young Kong; Jonghoe Byun
Journal:  Biomol Ther (Seoul)       Date:  2013-01       Impact factor: 4.634

Review 7.  From bench to bedside: immunotherapy for prostate cancer.

Authors:  Brian Wan-Chi Tse; Lidija Jovanovic; Colleen Coyne Nelson; Paul de Souza; Carl Andrew Power; Pamela Joan Russell
Journal:  Biomed Res Int       Date:  2014-09-04       Impact factor: 3.411

8.  Can glycoprofiling be helpful in detecting prostate cancer?

Authors:  Štefan Belický; Jan Tkac
Journal:  Chem Zvesti       Date:  2014-11-28       Impact factor: 2.097

9.  Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer.

Authors:  Gillian O'Hurley; Christer Busch; Linn Fagerberg; Björn M Hallström; Charlotte Stadler; Anna Tolf; Emma Lundberg; Jochen M Schwenk; Karin Jirström; Anders Bjartell; William M Gallagher; Mathias Uhlén; Fredrik Pontén
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

Review 10.  Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Authors:  Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2014-05-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.